Recommended colorectal cancer screening modalities vary with respect to safety, efficacy, and cost. Better understanding of the factors that influence patient preference is, therefore, critical for improving population adherence to colorectal cancer screening. To address this knowledge gap, we conducted a panel survey focused on three commonly utilized colorectal cancer screening options [fecal immunochemical test or guaiac-based fecal occult blood test (FIT/gFOBT), multi-target stool DNA (mt-sDNA) test, and colonoscopy] with a national sample of U.S. adults, ages 40–75 years and at average risk of colorectal cancer, in November 2019. Of 5,097 panelists invited to participate, 1,595 completed the survey (completion rate, 31.3%). Our results showed that when presented a choice between two colorectal cancer screening modalities, more respondents preferred mt-sDNA (65.4%) over colonoscopy, FIT/gFOBT (61%) over colonoscopy, and mt-sDNA (66.9%) over FIT/gFOBT. Certain demographic characteristics and awareness of and/or experience with various screening modalities influenced preferences. For example, uninsured people were more likely to prefer stool-based tests over colonoscopy [OR, 2.53; 95% confidence interval (CI), 1.22–5.65 and OR, 2.73; 95% CI, 1.13–7.47]. People who had heard of stool-based screening were more likely to prefer mt-sDNA over FIT/gFOBT (OR, 2.07; 95% CI, 1.26–3.40). People who previously had a stool-based test were more likely to prefer FIT/gFOBT over colonoscopy (OR, 2.75; 95% CI, 1.74–4.41), while people who previously had a colonoscopy were less likely to prefer mt-sDNA or FIT/gFOBT over colonoscopy (OR, 0.39; 95% CI, 0.24–0.63 and OR, 0.40; 95% CI, 0.26–0.62). Our survey demonstrated broad patient preference for stool-based tests over colonoscopy, contrasting the heavy reliance on colonoscopy for colorectal cancer screening in clinical practice and highlighting the importance of considering patient preference in colorectal cancer screening recommendations. Prevention Relevance: Our national survey demonstrated broad patient preference for stool-based tests over colonoscopy, contrasting the heavy reliance on colonoscopy for colorectal cancer screening in clinical practice and highlighting the importance of considering patient preference in colorectal screening recommendations.

中文翻译：

---

与结直肠癌筛查偏好相关的患者因素全国调查

推荐的结直肠癌筛查方式因安全性、有效性和成本而异。因此，更好地了解影响患者偏好的因素对于提高人群对结直肠癌筛查的依从性至关重要。为了解决这一知识差距，我们进行了一项小组调查，重点关注三种常用的结直肠癌筛查选项 [粪便免疫化学测试或基于愈创木脂的粪便潜血测试 (FIT/gFOBT)、多靶点粪便 DNA (mt-sDNA) 测试、和结肠镜检查] 于 2019 年 11 月对 40-75 岁、平均患结肠直肠癌风险的美国成年人进行了全国抽样调查。在受邀参加的 5,097 名小组成员中，1,595 人完成了调查（完成率，31.3%）。我们的结果表明，当在两种结直肠癌筛查方式之间进行选择时，更多的受访者更喜欢 mt-sDNA (65.4%) 而不是结肠镜检查，FIT/gFOBT (61%) 优于结肠镜检查，mt-sDNA (66.9%) 优于 FIT/gFOBT。某些人口统计特征以及对各种筛查方式的认识和/或经验会影响偏好。例如，与结肠镜检查相比，没有保险的人更喜欢基于粪便的检查 [OR, 2.53; 95% 置信区间 (CI)，1.22–5.65 和 OR，2.73；95% CI，1.13–7.47]。听说过基于粪便的筛查的人更喜欢 mt-sDNA 而不是 FIT/gFOBT（OR，2.07；95% CI，1.26-3.40）。与结肠镜检查相比，以前接受过粪便检查的人更可能更喜欢 FIT/gFOBT（OR，2.75；95% CI，1.74-4.41），而以前接受过结肠镜检查的人不太可能更喜欢 mt-sDNA 或 FIT /gFOBT 与结肠镜检查相比（OR，0.39；95% CI，0.24–0.63 和 OR，0.40；95% CI，0。26–0.62)。我们的调查表明，与结肠镜检查相比，患者更倾向于粪便检查，这与临床实践中对结肠镜检查进行结直肠癌筛查的严重依赖形成了对比，并强调了在结直肠癌筛查建议中考虑患者偏好的重要性。预防相关性：我们的全国性调查表明，与结肠镜检查相比，患者更倾向于粪便检查，这与临床实践中对结肠镜检查进行结直肠癌筛查的严重依赖形成鲜明对比，并强调了在结直肠筛查建议中考虑患者偏好的重要性。对比了在临床实践中对结肠镜检查进行结肠直肠癌筛查的严重依赖，并强调了在结肠直肠癌筛查建议中考虑患者偏好的重要性。预防相关性：我们的全国性调查表明，与结肠镜检查相比，患者更倾向于粪便检查，这与临床实践中对结肠镜检查进行结直肠癌筛查的严重依赖形成鲜明对比，并强调了在结直肠筛查建议中考虑患者偏好的重要性。对比了在临床实践中对结肠镜检查进行结肠直肠癌筛查的严重依赖，并强调了在结肠直肠癌筛查建议中考虑患者偏好的重要性。预防相关性：我们的全国性调查表明，与结肠镜检查相比，患者更倾向于粪便检查，这与临床实践中对结肠镜检查进行结直肠癌筛查的严重依赖形成鲜明对比，并强调了在结直肠筛查建议中考虑患者偏好的重要性。